Faced with manufacturing quality questions that caused the FDA to reject its potential Parkinson’s disease treatment, Impax Laboratories has hired a committee of specialists to oversee quality improvements at its California facility.
Biovail has this week sought to reassure its investors after the
news that US regulators issued the company with a Non Approval
letter for its new bupropion salt anti-depressant.
A combination therapy to help smokers kick the habit has begun
evaluation in Phase I pilot studies in the US. A sustained-release
formulation of Cary Pharmaceutical's QuitPak has been developed
with IntelGenx Technologies as...
